Spikevax JN.1 Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

COVID-19 mRNA vaccine (nucleoside modified)

Indications/Uses

Active immunisation to prevent COVID-19 disease caused by SARS-CoV-2 in individuals ≥6 mth (0.1 mg/mL) or ≥12 yr (50 mcg/0.5 mL).

Dosage/Direction for Use

IM Individual ≥12 yr 0.5 mL as single dose. 0.1 mg/mL Childn 6-11 yr Primary series: 2 doses of 0.5 mL. Administer 2nd dose 28 days after the 1st dose, 6 mth-5 yr Primary series: 2 doses of 0.25 mL. Administer 2nd dose 28 days after the 1st dose.

Contraindications

Hypersensitivity.

MIMS Class

Vaccines, Antisera & Immunologicals

ATC Classification

J07BN01 - covid-19, RNA-based vaccine ; Belongs to the class of covid-19 vaccines.

Regulatory Classification

POM

Presentation/Packing

Form

Spikevax JN.1 dispersion for inj (multidose vial) 0.1 mg/mL

Packing/Price

1's

Form

Spikevax JN.1 dispersion for inj (pre-filled syringe) 50 mcg/0.5 mL

Packing/Price

1's

Spikevax JN.1

Manufacturer:

Moderna TX